Velan Capital Investment Management LP Purchases New Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

Velan Capital Investment Management LP acquired a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 500,000 shares of the company’s stock, valued at approximately $1,595,000. Perspective Therapeutics makes up approximately 1.4% of Velan Capital Investment Management LP’s holdings, making the stock its 14th largest position. Velan Capital Investment Management LP owned approximately 0.74% of Perspective Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of CATX. Y Intercept Hong Kong Ltd acquired a new position in shares of Perspective Therapeutics during the 4th quarter worth $33,000. Aigen Investment Management LP bought a new position in Perspective Therapeutics in the fourth quarter valued at about $34,000. National Bank of Canada FI grew its position in Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after acquiring an additional 10,998 shares during the last quarter. ProShare Advisors LLC raised its stake in Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after acquiring an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics in the fourth quarter worth about $51,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Perspective Therapeutics

In related news, CFO Juan Graham bought 33,333 shares of the business’s stock in a transaction on Friday, March 28th. The stock was acquired at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. This trade represents a 1,649.33% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Johan M. Spoor acquired 22,026 shares of the business’s stock in a transaction dated Friday, March 28th. The stock was purchased at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the transaction, the chief executive officer now directly owns 59,383 shares of the company’s stock, valued at $133,017.92. This trade represents a 58.96% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 115,696 shares of company stock worth $256,344 over the last ninety days. 3.72% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CATX has been the subject of a number of research analyst reports. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, March 27th. Scotiabank assumed coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a report on Monday, March 31st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.50.

Perspective Therapeutics Stock Performance

Shares of NYSE:CATX opened at $2.63 on Monday. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $16.90. The business has a fifty day moving average price of $2.24 and a two-hundred day moving average price of $3.59.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.